Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
2-Step Haploidentical Transplant with Radiation-Based RIC
NCT05031897Phase 2Recruiting
- Sponsor
- Thomas Jefferson University
- Start
- Oct 2021
- Primary completion
- Apr 2032
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
A Phase 2 trial of cyclophosphamide, fludarabine, melphalan in acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), myelodysplastic syndrome (MDS), chronic lymphocytic leukemia (CLL), multiple myeloma (MM), sponsored by Thomas Jefferson University. Started Oct 2021; status: recruiting.
02
Drugs
cyclophosphamidefludarabinemelphalan
03
Conditions
acute myeloid leukemia (AML)acute lymphoblastic leukemia (ALL)myelodysplastic syndrome (MDS)chronic lymphocytic leukemia (CLL)multiple myeloma (MM)
Beyond the preview
Go deeper on NCT05031897.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05031897.